<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04090879</url>
  </required_header>
  <id_info>
    <org_study_id>CHRMS19-0129</org_study_id>
    <secondary_id>U54DA036114-06</secondary_id>
    <nct_id>NCT04090879</nct_id>
  </id_info>
  <brief_title>Low Nicotine Content Cigarettes in Vulnerable Populations: Affective Disorders</brief_title>
  <official_title>Low Nicotine Content Cigarettes in Vulnerable Populations: Affective Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brown University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Food and Drug Administration (FDA)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Vermont</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Brown University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      While the prevalence of smoking in the United States general population has declined over the&#xD;
      past 50 years, there has been little to no decline among people with mental health&#xD;
      conditions. Affective Disorders (ADs) are the most common mental health conditions in the US,&#xD;
      and over 40% of people with ADs are current smokers. A national policy of reducing the&#xD;
      nicotine content of cigarettes has the potential to reduce tobacco use, dependence, and&#xD;
      related adverse health outcomes. Controlled trials in psychiatrically-stable smokers have&#xD;
      shown that reducing the nicotine content in cigarettes can reduce cigarettes per day (CPD),&#xD;
      dependence and tobacco toxicant exposure, with few adverse consequences.&#xD;
&#xD;
      The goal of the proposed trial is to experimentally model whether increasing the availability&#xD;
      and appeal of an alternative, non-combusted source of nicotine (e-cigarettes) moderates the&#xD;
      effect of altering the nicotine in cigarettes in smokers with ADs. Additionally,&#xD;
      investigators will test whether allowing participants to personalize the flavor of the&#xD;
      e-liquid alters any moderating effects their availability may have on tobacco cigarette&#xD;
      smoking.&#xD;
&#xD;
      Daily smokers with current ADs will be recruited at Brown University and the University of&#xD;
      Vermont.&#xD;
&#xD;
      Investigators will study two research cigarettes referred to here as Research Cigarette 1&#xD;
      (RC1) and Research Cigarette 2 (RC2). One of these cigarettes will be a normal nicotine&#xD;
      content cigarette and the other will be a reduced nicotine content cigarette. Investigators&#xD;
      will study two e-cigarette conditions referred to here as E-Cigarette Condition 1 (EC1) and&#xD;
      E-Cigarette Condition 2 (EC2). Both e-cigarette conditions will involve the same commercially&#xD;
      available devices and same nicotine-containing e-liquid, but in one condition that e-liquid&#xD;
      will be available only in tobacco flavor while in the other condition that e-liquid will be&#xD;
      available in multiple flavors from which participants can choose based on personal taste&#xD;
      preference. Participants will be assigned to one of the following four study conditions: (1)&#xD;
      RC1 only; (2) RC2 only; (3) RC2 + EC1; (4) RC2 + EC2.&#xD;
&#xD;
      Participants will be asked to use only their assigned study products for 16 weeks. Outcome&#xD;
      measures include total CPD, cigarette demand assessed by behavioral economics-based purchase&#xD;
      tasks, craving, withdrawal, psychiatric symptoms, breath carbon monoxide (CO), biomarkers of&#xD;
      tobacco toxicant exposure, brain function and structure, and airway inflammation (fractional&#xD;
      nitric oxide concentration in exhaled breath [FeNO]).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 18, 2019</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double blind dosing of tobacco cigarette nicotine levels.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Cigarettes Per Day</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">232</enrollment>
  <condition>Tobacco Use Disorder</condition>
  <arm_group>
    <arm_group_label>RC 1 only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Research Cigarettes #1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RC 2 only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Research Cigarettes #2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RC 2 + EC 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Research Cigarettes #2 plus E-cigarettes #1 (participants receive tobacco flavor only)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RC 2 + EC 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Research Cigarettes #2 plus E-cigarettes #2 (participants can choose among varying flavors)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Either normal nicotine content cigarettes (15.8mg/g) or reduced nicotine content cigarettes (0.4mg/g)</intervention_name>
    <description>1) Altering the nicotine content of the tobacco research cigarette</description>
    <arm_group_label>RC 1 only</arm_group_label>
    <arm_group_label>RC 2 + EC 1</arm_group_label>
    <arm_group_label>RC 2 + EC 2</arm_group_label>
    <arm_group_label>RC 2 only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>E-Cigarettes</intervention_name>
    <description>1) Altering the availability of e-cigarettes; 2) Altering option to personalize the e-liquid in the e-cig condition</description>
    <arm_group_label>RC 2 + EC 1</arm_group_label>
    <arm_group_label>RC 2 + EC 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Between 21 years and 70 years old&#xD;
&#xD;
          -  Must have current diagnosis of an Affective Disorder.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Being without an Affective Disorder&#xD;
&#xD;
          -  Younger than 21 years old&#xD;
&#xD;
          -  Older than 70 years old&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer W Tidey, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brown University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shirley Plucinski</last_name>
    <phone>9788752361</phone>
    <email>shirley.plucinski@uvm.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Brown University</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Tidey, Ph.D</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Vermont</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shirley Plucinski</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>September 13, 2019</study_first_submitted>
  <study_first_submitted_qc>September 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2019</study_first_posted>
  <last_update_submitted>May 11, 2021</last_update_submitted>
  <last_update_submitted_qc>May 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brown University</investigator_affiliation>
    <investigator_full_name>Jennifer Tidey</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Biomarkers of Exposure</keyword>
  <keyword>Compensatory Smoking</keyword>
  <keyword>Nicotine Dependence</keyword>
  <keyword>Reduced Nicotine Cigarettes</keyword>
  <keyword>Affective Disorders</keyword>
  <keyword>Tobacco Withdrawal</keyword>
  <keyword>Vulnerable Populations</keyword>
  <keyword>E-Cigarettes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Tobacco Use Disorder</mesh_term>
    <mesh_term>Mood Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

